Skip to content

Trial Summary

CannabisCINV: A placebo-controlled trial evaluating an oral THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting in patients of any known malignancy receiving chemotherapy.

Acronym:

CANNABIS CINV

ACTRN/NCT /ethics:

ACTRN12616001036404

Scientific title:

Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting

Sponsor / Cooperative group:

Health Administration Corporation, through the NSW Ministry of Health, for and on behalf of the NSW Government

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypePrevention
PhasePhase I
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2016-11-30
Anticipated End Date2021-10-30

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
EmailHannah.adelson@sa.gov.au
Phone08 8206 4835
Principal InvestigatorDr Muhammad Nazim Abbas
Recruitment StatusRecruiting